SuperworthIllumina, Inc. ILMN
Medical - Diagnostics & Research, Healthcare
$267.76
−2.11%
- Market cap
- $40.4B
- PE
- 49.9×
- 10y median 50.6×
- Forward PE
- Price to sales
- 9.0×
- EV/EBIT
- 47.4×
- Revenue, 12 months
- $4.5B
- +5% on a year ago
- Net margin
- 18.4%
- Free cash flow yield
- 2.3%
Illumina trades at 49.9× trailing earnings, near its ten-year median. Revenue was $4.5B over the last twelve months, up 5% on a year earlier with a 18% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B | $1.1B | $1.1B | $1.1B | $1.1B−2% | $1B−3% | $1.1B−5% | $1.1B+0% | $1.2B+5% | $1.1B+5% | $1.2B+9% | |
| Cost of revenue | $448M | $409M | $391M | $335M | $376M−16% | $358M−13% | $364M−7% | $351M+5% | $400M+6% | $370M+3% | $389M+7% |
| Gross profit | $674M | $667M | $721M | $745M | $728M+8% | $683M+2% | $695M−4% | $733M−2% | $759M+4% | $721M+6% | $770M+11% |
| R&D | $341M | $339M | $325M | $253M | $256M−25% | $252M−26% | $247M−24% | $229M−10% | $239M−7% | $240M−5% | $252M+2% |
| SG&A | $485M | $439M | $147M | $239M | $271M−44% | $267M−39% | $234M+59% | $277M+16% | $309M+14% | $272M+2% | $273M+17% |
| −$164M | −$111M | −$1.6B | $741M | $175M | $164M | $214M | $227M−69% | $201M+15% | $209M+27% | $245M+15% | |
| Interest expense | $18M | $18M | $20M | $36M | $25M+39% | $25M+39% | $25M+25% | $25M−31% | $26M+4% | $24M−4% | $0 |
| Pre-tax income | −$167M | −$109M | −$2B | $720M | $187M | $182M | $306M | $220M−69% | $377M+102% | $157M−14% | $260M−15% |
| $8M | $17M | $12M | $15M | $0 | $51M+200% | $71M+492% | $70M+367% | $43M | $23M−55% | $53M−25% | |
| Net income | −$176M | −$126M | −$2B | $705M | $186M | $131M | $235M | $150M−79% | $334M+80% | $134M+2% | $207M−12% |
| −$1.11 | −$0.79 | −$12.48 | $4.42 | $1.17 | $0.82 | $1.49 | $0.98−78% | $2.17+86% | $0.87+6% | $1.35−9% | |
| 159M | 159M | 159M | 160M | 160M+1% | 159M+0% | 157M−1% | 154M−4% | 154M−4% | 154M−3% | 153M−3% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times Illumina's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ILMNIllumina, Inc. | $40.4B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| IDXXIDEXX Laboratories, Inc. | $39.9B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| IQVIQVIA Holdings Inc. | $42.5B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| WATWaters Corporation | $42.8B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| AAgilent Technologies, Inc. | $47.7B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| MTDMettler-Toledo International Inc. | $30.7B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.3B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.1B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| DHRDanaher Corporation | $153.6B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $244.8B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $42.5B | 34.5× | 32.8× | 6.1× | +8% | 15.0% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .